explore -WSS

explore

author：leisure time 2025-09-27 12:57:10 - browse：125

illustration of one blue dna strand — Adobe

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Ukraine and a new approach to mental health in war

Wikipedia

WSS

Lasker Awards 2023: Winners in biomedical research

Fatty liver disease was alleviated by Lilly’s ‘triple

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Biotech lab space demand falls sharply

AstraZeneca lung cancer study comes in below expectations

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

focus

explore

Wikipedia

Medicare proposal to cover medical devices draws a mixed reaction

Biotech stock slump in 2023: awaiting the turnaround

Drug repurposing or repositioning? The language matters

Undocumented workers face uncertainty as immigration law takes effect in Florida

23andMe had bad news about my health. I wish a person had delivered it

Microbiome research is starting to find links to chronic diseases

Anesthesiologist group: stop taking Ozempic before surgery

AstraZeneca lung cancer study comes in below expectations

In age of alternative facts, a scholarly course on calling out crap

Second xenotransplant done with gene

knowledge

CDC advisers recommend seasonal use of Pfizer RSV shot

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Readout LOUD podcast: possible new ALS drug, artificial wombs

EpiPen alternative approval delay highlights citizen petition issue

Beware reading your test results before your doctor does

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

explore

Wikipedia

leisure time

focus